| 李月月 张立婷 张璨 朱克祥 李俊峰 陈青锋.DC-CIK治疗对晚期肝细胞癌患者免疫功能及循环肿瘤细胞的影响[J].,2017,17(6):1066-1069 |
| DC-CIK治疗对晚期肝细胞癌患者免疫功能及循环肿瘤细胞的影响 |
| The Effects of DC-CIK Therapy on Immune Function and Circulating TumorCells in Patients with Advanced Hepatocellular Carcinoma |
| |
| DOI： |
| 中文关键词: DC-CIK细胞治疗 肝细胞癌 甲胎蛋白 循环肿瘤细胞 T细胞亚群 |
| 英文关键词: DC-CIK cell therapy Hepatocellular carcinoma AFP Circulating tumor cells T cell subsets |
| 基金项目:甘肃省科技重大项目（1302FKDA029）；甘肃省自然科学基金项目（1506RJZA263） |
|
| 摘要点击次数: 1044 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：研究DC-CIK 细胞治疗对晚期肝细胞癌患者甲胎蛋白、免疫功能及循环肿瘤细胞数的影响。方法：选取2013 年至2015
年我院收治的26例肝细胞癌并伴有复发或转移的患者，对其治疗前后甲胎蛋白、免疫功能及循环肿瘤细胞数的数据进行分析，
比较DC-CIK 细胞治疗前后甲胎蛋白、循环肿瘤细胞、免疫功能的变化。根据细胞治疗次数分为1 次组及>1 次组，比较两组免疫
功能的变化。结果：DC-CIK 细胞治疗前甲胎蛋白为(603.32± 155.78) ng/mL，细胞回输后为(571.24± 147.49) ng/mL，差异无统计学
意义(P＞0.05)。DC-CIK 细胞治疗前及细胞回输后CTC检测阳性率分别为81.8 %、36.4 %；治疗前及回输后循环肿瘤细胞数量分
别为(8.36± 10.642)、(1.55± 2.464)，细胞治疗前后比较差异均有统计学意义(P<0.05)。细胞治疗前1 天T 细胞亚群CD3+、
CD3+CD4+、CD3+CD8+、CD4/CD8 分别为(66.05± 15.31)%、(41.89± 12.33)%、(23.15± 8.05)%、(2.10± 0.77)，回输后分别为(69.69±
12.91)%、(44.80± 11.11)%、(23.13± 7.12)%、(2.29± 0.91)，治疗前后比较差异无统计学意义(P>0.05)。细胞治疗次数1 次组和>1 次
组免疫功能变化差异无统计学意义(P>0.05)。结论：DC-CIK 细胞治疗可减少肝细胞癌伴复发或转移患者循环肿瘤细胞的数量，但
对甲胎蛋白和免疫功能无明显影响。 |
| 英文摘要: |
| Objective:To investigate the effects of DC-CIK cell therapy on AFP, immune function and number of circulating
tumor cell in patients with advanced hepatocellular carcinoma.Methods:26 cases of hepatocellular carcinoma with recurrence or
metastasis were selected from 2013 to 2015, the data of AFP, immune function and number of circulating tumor cell were analyzed
before and after DC-CIK treatment, the changes of AFP, immune function and number of circulating tumor cell were compared. Based on
frequency of cell therapy, the patients were divided into 1 time group and more than 1 time group, the changes of immune function were
compared between two groups.Results:AFP was (603.32± 155.78) ng/mL one day before DC-CIK cell therapy and (571.24± 147.49)
ng/mL after reinfusion (P>0.05). One day before DC-CIK cell therapy and after cell transfusion, the positive rate of CTC were 81.8 %,
36.4 % respectively; number of circulating tumor cells were (8.36 ± 10.642), (1.55 ± 2.464) one day before treatment and after the
reinfusion respectively (P<0.05). The CD3+, CD3+ CD4+, CD3+ CD8+, CD4/CD8 were (66.05± 15.31) %, (41.89± 12.33) %, (23.15±
8.05) %, (2.10± 0.77) one day before treatment and (69.69± 12.91) %, (44.80± 11.11) %, (23.13± 7.12) %, (2.29± 0.91 ) after infusion
respectively (P>0.05). The immune function showed no statistic significance between 1 time group and more than 1 time group (P>0.05).Conclusion:DC-CIK cell therapy could reduce number of circulating tumor cells in patients suffering from hepatocellular carcinoma
with recurrence or metastasis, but had no significant effect on the serumAFP level and immune function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
